Tuesday, 1 October 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 01 October 2024
News

Complicated drug still under review

Posted 30 September 2024 AM

The TGA has confirmed that Apellis' eye drug Syfovre is still being considered and that no decision has yet been made after Europe's advisory committee, the CHMP, refused granting the company marketing authorisation yet again this month.

Last week, the CHMP confirmed its initial recommendation to refuse the granting of a marketing authorisation for Syfvore, crushing Apellis' hopes to bring the first treatment for geographic atrophy (GA) to market in Europe.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (6)

Sales & Customer Relations (15)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (8)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.